NovoLog, Novo Nordisk

U.S. lawmakers attempting to cut the cost of insulin for more than a million Americans to $35 per month are unlikely to succeed as November elections draw near and complicate bipartisan support, health policy and political experts say.

On Thursday, members of both the U.S. House of Representatives and the U.S. Senate introduced legislation that targets efforts that have limited competition, which keeps the price of prescription drugs high.

U.S. Senate Majority Leader Chuck Schumer said on March 22 he intends to hold votes this spring on a bill that would cap the cost of insulin, a life-sustaining diabetes drug.

U.S. President Joe Biden on February 10 said he expected inflation to start to ease during 2022 as supply chain logjams clear up, while saying his administration was already helping ease shortages, as new data showed the biggest jump in consumer prices in 40 years.

As 2022 unfolds, pharmaceutical companies were quick to implement price increases on hundreds of prescription medications. According to research company 46brooklyn, drug manufacturers raised prices on 460 different medicines in the first days of January.

Biogen

Biogen announced that effective January 1, 2022, the company will cut the wholesale acquisition cost of the Alzheimer’s drug Aduhelm (aducanumab) in half.

As the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting presents many clinical trial updates, there appears to be a theme: access to drugs and pricing.

President Donald Trump signed a new executive order aimed at lowering drug prices in the United States by linking them to those of other nations and expanding the scope of a July 2020 action.

U.S. President Donald Trump signed four executive orders aiming at lowering prices that Americans pay for prescription drugs as he faces an uphill re-election battle and criticism over his handling of the coronavirus pandemic.

Roche struck a $1.7 billion cancer drug pact with Blueprint Medicines, as advances in genetic testing for rare mutations drive lucrative deals for expensive treatments.